Altre lingue Galmed Pharmaceuticals Ltd.

Azioni

GLMD

IL0011313900

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 30/04/2024			Variaz. 5gg	Var. 1 gen.
0,352 ^USD	-7,12%		-2,60%	-22,64%

04/04	Galmed Pharmaceuticals Ltd. Riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
15/03	Galmed Pharmaceuticals Ltd. annuncia la concessione di un nuovo brevetto per la combinazione di Aramchol e Resmetirom (MGL-3196, REZDIFFRA) per il trattamento della fibrosi epatica e del Nash	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	15/03
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis	15/03
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K	22/11
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	21/11
Sector Update: Health Care	21/11
Top Midday Decliners	21/11
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study	20/11
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study	20/11
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	26/09/23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	25/09/23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	22/09/23
Galmed Pharmaceuticals: Q2 Earnings Snapshot	10/08/23
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K	09/08/23
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K	18/07/23
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering	17/07/23
Top Midday Decliners	14/07/23
Galmed Pharmaceuticals Prices $7 Million Securities Offering; Shares Slump	14/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Galmed Pharmaceuticals Ltd.

Azioni

GLMD

IL0011313900

Altre lingue

Filtri